Purdue Develops New Strategy for Drug Discovery

Posted: Updated:
Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials. Not-for-profit Boilermaker Health Innovations is Purdue's unique strategy to fund researchers up to Phase 1 clinical trials.

Research scientists often confront the “valley of death”—the gaping hole that exists between laboratory discoveries and their transformation into new medical treatments and products. And the most lethal factor for most researchers is money. However, Purdue University is blazing an unusual trail to help make ends meet in translational research. Rather than rely on traditional sources, the university has formed a not-for-profit startup to take discoveries from the lab up to Phase 1 human clinical trials.

“We develop a lot of drugs [at Purdue]; there aren’t many academic institutions or cancer centers [in our position]—with 14 of their drugs that are synthesized at their own institution in human clinical trials,” says Purdue Center for Cancer Research Robert Wallace Miller Director Dr. Tim Ratliff. “It’s a real strength here, and we want to improve and speed the process.”

Translating basic research into life-changing treatments is one initiative of Purdue Moves, a program that involves 10 university initiatives designed to enhance research, education and the school’s global impact.

Purdue’s Center for Cancer Research is one of only seven basic science research centers in the country designated by the National Cancer Institute. While Ratliff describes the center as a very efficient entity that can “move things forward in a rapid manner,” the process is still slower than scientists like.

Researchers typically rely on external funding from government sources to help them uncover a discovery, but beyond that, the money often dries up.

“[Government sources] don’t fund drugs from the discovery through all these routine processes you have to go through to get that drug ready to go into clinical trials,” says Ratliff. “You have to take these drugs and develop them, so that we understand the toxicities associated with them, their distribution in the body and other fundamental things before we get into the clinic.”

This is when most scientists encounter the “valley of death,” but Purdue believes it can finance the very expensive process with its newly formed Boilermaker Health Innovations, a not-for-profit startup that represents a unique way to fund the gap. Boilermaker Health believes it will be much speedier than the traditional route of forming for-profit companies that aim to attract investments to reach human clinical trials.

Once Boilermaker Health has funded a scientist through early research, Ratliff says it will spin-off a for-profit company to develop the compound and take it through U.S. Food and Drug Administration approval or sell the drug to a large pharmaceutical company.

“As we develop these drugs from very early stages, we envision those drugs will gain value,” says Ratliff. “While we’re a not-for-profit company, that value will create a fund in Boilermaker Health that will allow us, over time, to become independent and support our cancer research and drug discovery very efficiently through the use of those funds.”

Ratliff acknowledges the unconventional model begs the question of how Boilermaker Health will get its first infusion of cash; he says it will rely on Purdue donors, federal funding agencies and private foundations. The Purdue Research Foundation is also matching each donation, up to a total of $1.3 million.

Additionally, Boilermaker Health is considering an alumni crowdfunding effort. The startup has already received a commitment of $175,000 and is “pushing hard” to collect more donations.

“Earning the match would give us $2.6 million, and that would be sufficient to move our first compound through pre-clinical analyses,” says Ratliff. “Once Boilermaker Health gets the drug through the proof of principle clinical trial, that will enable us to sell the product at a higher value, and that higher value will bring revenue back in. The money that we get back, we re-invest into drug discovery, amplifying our ability to move drugs through the valley of death.”

An external advisory committee is currently evaluating compounds in the Purdue pipeline to select the first for Boilermaker Health to “shepherd.” Leaders are hopeful the university’s unique strengths in drug discovery will also pave an unconventional path to patients.

Ratliff says there’s one question he gets the most about Boilermaker Health Innovations.
Ratliff says an external advisory committee will select the first compound that Boilermaker Health Innovations will “shepherd.”
  • Perspectives

    • Startup Spirit Fuels Growth

      As the South Bend - Elkhart Region celebrates a $42.4 million grant from Lilly Endowment Inc., we know that the work to make the best investment with it is really just beginning. The spirit of entrepreneurship has been a vibrant part of our region for decades and the story of our family company could be somewhat of a guidebook for the region as it ventures forward. ITAMCO began as a dream of my uncle Donald Neidig and my father Noble Neidig to have their own business.

    More

Events



  • Most Popular Stories

    • The Waterside project aims to transform 100-acres of the former GM Stamping Plant site. (photo courtesy of Ambrose Property Group)

      Ambrose, Glick Partner on Waterside

      Indianapolis-based Ambrose Property Group has announced a key partnership for the redevelopment of the former GM Stamping Plant in downtown Indianapolis. The commercial real estate firm is teaming up with the Gene B. Glick Co. to build and manage apartments as part of the $1.4 billion mixed-use redevelopment project. Ambrose says the partnership is also part of plans to catalyze "philanthropic and community-centric strategies to strengthen Indianapolis." The firm also...

    • NIBCO is headquartered in Elkhart. (photo courtesy of NIBCO)

      Companies Detail Closures, Layoffs

      Four companies have announced plans to lay off a total of nearly 300 employees. In separate notices filed with the state, the companies say the moves will affect workers in Indianapolis, Fort Wayne, Charlestown and Peru.

    • (Rendering provided by the city of Fishers.)

      Flexware to Break Ground on Headquarters

      Fisher’s based engineering servicing firm, Flexware Innovation Inc., will break ground Thursday on its new headquarters the Nickel Plate District Amphitheater. The $3.5 million project will feature a 35,000-square-foot office building with 12,000-square feet of office space for Flexware and what it calls “a build-to-suit area” in the remaining space. 

    • (rendering courtesy of Brightmark Energy)

      Construction to Begin on Plastics-to-Fuel Plant

      California-based Brightmark Energy will today break ground on its $260 million plastics-to-fuel plant in the northeast Indiana town of Ashley. The 112,000-square-foot facility, which the company says will be the first of its kind in the nation, is expected to create 136 full-time jobs when fully operational. The plant will use a state-of-the-art process to recycle plastic waste that has reached the end of its useful life, including items that normally cannot be recycled, such as...

    • Photo courtesy of Lafayette Elementary School

      Hammond to Close Three Schools, to Cut Jobs

      The  School City of Hammond board has voted to close three schools and cut 130-150 positions. Our partners at The Times of Northwest Indiana report Columbia and Lafayette Elementary schools, and the Miller School will close after this school year.